Abstract Details

Title Implementing the CMS GUIDE Dementia Care Model in a Community Neurology Practice with Digital Tools, Standardized Scales, and Embedded Clinical Trial Recruitment

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P5 - Poster Session 5 (11:45 AM-12:45 PM)

Poster/Presentation
Number 12-011

Objective To evaluate the feasibility of implementing the CMS Guiding an Improved Dementia Experience (GUIDE) model in a community neurology practice using digital platforms, standardized scales, and integrated clinical trial recruitment.

Background The GUIDE model establishes structured dementia care pathways requiring standardized assessments for both patients and caregivers. Evidence from community neurology settings remains limited. Digital tools may reduce implementation burden, improve caregiver engagement, and facilitate research integration.

Design/Methods GUIDE was implemented across a multi-site community neurology practice. The program included: (1) digital cognitive screening via a voice-recognition platform; (2) electronic administration of GUIDE-required scales—functional (FAQ, ADLs/IADLs), behavioral (NPI-Q), depression (GDS), caregiver burden (Zarit), and patient-reported outcomes (PROMIS Global Health); (3) care navigators coordinating APOE testing, MRI scheduling, ARIA monitoring, and linkage to community resources; and (4) embedded recruitment for Alzheimer’s clinical trials through a partnership with a community research network.

Results During the first 90 days of GUIDE implementation, 141 participants completed required assessments with >80% electronic form completion, confirming workflow feasibility. Mean dementia staging score was 4.5 ± 1.0 (mild–moderate range), mean GDS 7.2 ± 1.8, PROMIS Global Health 29 ± 5.9, and Zarit caregiver burden 41 ± 15.7, indicating moderate caregiver stress. Higher dementia severity correlated with greater caregiver burden (r = 0.62, p < 0.01) and lower PROMIS Global Health scores (r = –0.58, p < 0.01). Patients reporting better perceived health and quality of life demonstrated lower caregiver stress. Structured scoring data also enabled pre-identification of clinical trial-eligible patients, enhancing recruitment efficiency through the Profound Research partnership. Additional data collection is ongoing to evaluate longitudinal impact.

Conclusions Community neurology practices can effectively operationalize GUIDE using digital tools to deliver required assessments, engage caregivers, and support research. Early results demonstrate feasibility and scalability of a digital, community-based dementia care model that bridges clinical care with Alzheimer’s trial participation.

Authors/Disclosures
Gregory Sahagian, MD, FAAN PRESENTER	Dr. Sahagian has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. The institution of Dr. Sahagian has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. The institution of Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Sahagian has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Argenx. The institution of Dr. Sahagian has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Sahagian has received intellectual property interests from a discovery or technology relating to health care.
Vidar Vignisson	Vidar Vignisson has stock in Intraneuron, LLC. Vidar Vignisson has received intellectual property interests from a discovery or technology relating to health care.
Tariq Vidarsson	An immediate family member of Mr. Vidarsson has stock in Intraneuron, LLC. An immediate family member of Mr. Vidarsson has received intellectual property interests from a discovery or technology relating to health care.
Ivan X. Rojas, Memory Care Coordinator	Mr. Rojas has nothing to disclose.
Andrew G. Inocelda, PA (The Neurology Center)	An immediate family member of Mr. Inocelda has received personal compensation for serving as an employee of Orthofix.

��ɫ��

��ɫ��